226
Participants
Start Date
May 31, 2011
Primary Completion Date
March 31, 2014
Study Completion Date
April 30, 2014
IPI 504 plus Docetaxel
"450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 \& 15 during each 21 day cycle~75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)"
Placebo plus Docetaxel
"450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 \& 15 during each 21 day cycle~75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)"
Országos Korányi TBC és Pulmonológiai Intézet, Budapest
Országos Korányi TBC és Pulmonológiai Intézet, Budapest
Mátrai Gyógyintézet, Mátraháza
Pándy Kálmán Megyei Kórház, Gyula
Zala Megyei Kórház, Zalaegerszeg
Sopron MJV Erzsébet Kórház, A DEOEC Oktató Kórháza, Sopron
National Taiwan University Hospital, Taipei
Tri-Service General Hospital, Taipei
Broome Oncology, LLC, Johnson City
Memorial Sloan-Kettering Cancer Center, New York
University of Rochester, Rochester
Virginia Cancer Institute, Richmond
Piedmont Hematology Oncology Associates, PLLC, Winston-Salem
Blumenthal Cancer Center, Charlotte
Charleston Hematology Oncology Associates, PA, Charleston
Cancer Centers of the Carolinas, Seneca
Florida Cancer Specialists and Research Institute, St. Petersburg
Florida Cancer Specialists, Fort Myers
Sarah Cannon Cancer Center, Nashville
Chattanooga Oncology and Hematology Associates, PC, Chattanooga
Owsley Brown Frazier Cancer Center-Louisville Downtown, Louisville
China Medical University Hospital, Taichung
Taichung Veterans General Hospital, Taichung
Signal Point Clinical Research Center, LLC, Middletown
Oncology Hematology Care, Inc., Cincinnati
Central Indiana Cancer Centers, Carmel
Indiana University, Indianapolis
Community Hospital, Munster
Floyd Memorial Cancer Center of Indiana, New Albany
Indiana University Health Ball Memorial Hospital, Muncie
Ann Arbor Hematology Oncology Associates, Ann Arbor
Karmanos Cancer Institute, Detroit
Sparrow Regional Cancer Center, Lansing
Metro Health Cancer Center, Wyoming
Southeast Nebraska Cancer Center, Lincoln
Tulane University, New Orleans
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
Texas Oncology-Tyler, Tyler
Texas Oncology-Arlington South, Arlington
University of Utah Hospital and Clinics, Salt Lake City
Ironwood Cancer and Research Center, Chandler
American Institute of Research, Whittier
Wilshire Oncology Medical Group, Inc., Rancho Cucamonga
University of California Irvine Medical Center, Orange
PMK Medical Group, Inc., Oxnard
Providence Portland Medical Center, Portland
Willamette Valley Cancer Institute and Research Center, Eugene
Puget Sound Cancer Centers, Edmonds
Spitalul Municipal Ploiesti, Ploieşti
Blokhin Cancer Research Center of Russia, Dept. of clinical pharmacology, Moscow
"Non-State Central Clinical Hospital # 2 named N.A. Semashko of OAO RGD", Moscow
City Oncology Hospital # 62, Moscow Region
"Institutul Oncologic Prof. Dr. I. Chiricuta", Cluj-Napoca
"Spitalul de Urgenta Constantin Opris", Baia Mare
"State Budget Institution of Healthcare Chelyabinsk Regional Clinical Oncology Dispensary", Chelaybinsk
Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu
Arizona Oncology Associates, Tucson
Yale Cancer Center, New Haven
Massachusetts General Hospital, Boston
National Cancer Center, Goyang-si
Inha University Hospital, Jung Gu
Chonnam National University Hwasun Hospital, Hwasun
Dong-A University Medical Center, Busan
Severance Hospital,Yonsei University Health System, Seoul
Asan Medical Center, Seoul
Lead Sponsor
Infinity Pharmaceuticals, Inc.
INDUSTRY